Symbol="ALGS"
AssetType="Common Stock"
Name="Aligos TherapeuticsÂ Inc"
Description="Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California."
CIK="1799448"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="37787300"
EBITDA="-83857000"
PERatio="None"
PEGRatio="None"
BookValue="1.974"
DividendPerShare="0"
DividendYield="0"
EPS="-1.89"
RevenuePerShareTTM="0.329"
ProfitMargin="0"
OperatingMarginTTM="-6.11"
ReturnOnAssetsTTM="-0.323"
ReturnOnEquityTTM="-0.702"
RevenueTTM="14059000"
GrossProfitTTM="-71170000"
DilutedEPSTTM="-1.89"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.059"
AnalystTargetPrice="4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.788"
PriceToBookRatio="0.351"
EVToRevenue="69.48"
EVToEBITDA="0.793"
Beta="2.233"
num_52WeekHigh="2.41"
num_52WeekLow="0.84"
num_50DayMovingAverage="1.021"
num_200DayMovingAverage="1.18"
SharesOutstanding="39847800"
DividendDate="None"
ExDividendDate="None"
symbol="ALGS"
open="0.89"
high="0.90"
low="0.86"
price="0.90"
volume="87576.00"
latest_trading_day="2023-08-02"
previous_close="0.88"
change="0.02"
change_percent="2.0909%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="68"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="32"
Volume_recent_avg="178502"
Change_recent_avg="-0.01"
Delta_recent_avg="0.1"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-1.03"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="32"
Aroon_momentum_negative="68"
image_negative_thumbnail_id_1="128"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0048.jpeg"
image_negative_thumbnail_id_2="121"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0055.jpeg"
image_neutral_thumbnail_id_1="570"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0029.jpeg"
image_neutral_thumbnail_id_2="560"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_positive_thumbnail_id_1="692"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0016.jpeg"
image_positive_thumbnail_id_2="622"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0086.jpeg"
image_professor_thumbnail_id_1="1192"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
image_professor_thumbnail_id_2="1186"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
